Therefore, inhibition of TGF-β/Mst through a novel class of antagonists could provide rationale justification not only for promoting muscle mass as expected, but also for the treatment of obesity and related metabolic syndromes. This evidence concerns the gene TGFB1 and obesity due to melanocortin 4 receptor deficiency.